US5798334A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical compositions for scarless tissue repair and regeneration and methods related thereto
Assignee: Colla-Gene Inc
•
Filing: 1995-09-28
•
Granted: 1998-08-25
•
Expires: 2015-09-28
Abstract
Abstract The invention relates to a pharmaceutical composition for normalizing the fibrogenic effect of an agonist which comprises an effective amount of an agonist to stimulate normal collagen synthesis together with an effective amount of an antagonist to reduce the agonist-mediated increase of collagen synthesis and collagen gene expression, together with a pharmaceutically acceptable carrier. The invention also relates to a method of normalizing the fibrogenic effect of an agonist with said composition.
Inventors
- 👤 Kenneth R. Cutroneo
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 12:35
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1841
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
82 words
A pharmaceutical composition for bringing the level back to control the fibrogenic effect of a fibrotic growth factor TGFB-1, which acts through the serine threonine kinase signal transduction mechanism and causes scarring, which comprises an effective amount of said growth factor to stimulate collagen synthesis, and an effective amount of an glucocosticoid to reduce the growth factor-mediated increased of collagen synthesis and collagen gene expression, together with a pharmaceutically acceptable carrier in a mammal suffering from a wound or injury repair disorder.
Claim 2
Dependent Claim
82 words
A pharmaceutical composition for bringing the level back to control the fibrogenic effect of a fibrotic growth factor TGFB-1, which acts through the serine threonine kinase signal transduction mechanism and causes scarring, which comprises an effective amount of said growth factor to stimulate collagen synthesis, and an effective amount of an glucocosticoid to reduce the growth factor-mediated increased of collagen synthesis and collagen gene expression, together with a pharmaceutically acceptable carrier in a mammal suffering from a wound or injury repair disorder.
Claim 3
Dependent Claim
12 words
The pharmaceutical composition according to claim 1 wherein the glucocorticoid is dexamethasone.
Claim 4
Dependent Claim
20 words
The pharmaceutical composition according to claim 1 in which the ratio of the fibrotic growth factor TGFB-1, glucocorticoid is 1:100.
Claim 5
Dependent Claim
25 words
The pharmaceutical composition according to claim 1 wherein the carrier is a cream, a gel, an aerosol, a solution, or a powder for topical application.
Claim 6
Dependent Claim
23 words
The pharmaceutical composition according to claim 1 incorporated in a patch, a sterile dressing, or an absorbable dressing for topically covering a wound.
Claim 7
Dependent Claim
21 words
The pharmaceutical composition according to claim 1 incorporated in a biopolymer or a polymer for contacting or implanting into a wound.
Claim 8
Dependent Claim
37 words
A method of normalizing the fibrogenic effect of a fibrotic growth factor which comprises administering to a mammal suffering from a wound or an injury repair disorder an effective amount of the pharmaceutical composition of claim 1.
Claim 9
Dependent Claim
13 words
The method according to claim 7 wherein the fibrotic growth factor is TGFB-1.
Claim 10
Dependent Claim
11 words
A method according to claim 7 wherein the glucocorticoid is dexamethasone.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-08-24 | 2002-02-23 | 2002-08-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-08-24 | 2006-02-23 | 2006-08-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-08-24 | 2010-02-23 | 2010-08-25 | $7700.00 | Window Closed / Lapsed |